NasdaqGS:GERN

Stock Analysis Report

Executive Summary

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Geron's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.6%

NasdaqGS:GERN

1.7%

US Biotechs

2.1%

US Market


1 Year Return

-64.3%

NasdaqGS:GERN

-9.1%

US Biotechs

-0.04%

US Market

GERN underperformed the Biotechs industry which returned -8.8% over the past year.

GERN underperformed the Market in United States of America which returned 0.2% over the past year.


Share holder returns

GERNIndustryMarket
7 Day3.6%1.7%2.1%
30 Day24.1%0.7%-3.2%
90 Day-7.1%2.4%2.8%
1 Year-64.3%-64.3%-8.3%-9.1%2.2%-0.04%
3 Year-46.1%-46.1%11.9%8.1%41.5%32.3%
5 Year-38.2%-38.2%5.2%0.3%55.0%37.8%

Price Volatility Vs. Market

How volatile is Geron's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Geron undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Geron's share price is below the future cash flow value, and at a moderate discount (> 20%).

Geron's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Geron is loss making, we can't compare its value to the US Biotechs industry average.

Geron is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Geron, we can't assess if its growth is good value.


Price Based on Value of Assets

Geron is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Geron expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

36.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Geron's revenue is expected to grow significantly at over 20% yearly.

Geron's earnings are expected to grow significantly at over 20% yearly.

Geron's revenue growth is expected to exceed the United States of America market average.

Geron's earnings growth is expected to exceed the United States of America market average.

Geron's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Geron will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Geron performed over the past 5 years?

-3.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Geron does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Geron's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Geron's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Geron has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Geron has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Geron improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Geron's financial position?


Financial Position Analysis

Geron is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Geron has no long term commitments.


Debt to Equity History and Analysis

Geron has no debt.

Geron has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Geron has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Geron has sufficient cash runway for more than 3 years based on current free cash flow.

Geron has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 9.8% each year.


Next Steps

Dividend

What is Geron's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Geron's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Geron's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Geron has not reported any payouts.

Unable to verify if Geron's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Geron has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Geron's salary, the management and board of directors tenure and is there insider trading?

6.7yrs

Average management tenure


CEO

Chip Scarlett (68yo)

7.9yrs

Tenure

US$2,772,509

Compensation

Dr. John A. Scarlett, also known as Chip, M.D., has been the Chief Executive Officer of Geron Corporation since joining in September 2011 and its President since January 5, 2012. Dr. Scarlett is Chairman o ...


CEO Compensation Analysis

Chip's remuneration is higher than average for companies of similar size in United States of America.

Chip's compensation has increased whilst company is loss making.


Management Age and Tenure

6.7yrs

Average Tenure

55yo

Average Age

The average tenure for the Geron management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

0.7yrs

Average Tenure

67yo

Average Age

The average tenure for the Geron board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Stephen Rosenfield (69yo)

    Executive VP

    • Tenure: 7.6yrs
    • Compensation: US$1.01m
  • Melissa A. Behrs (55yo)

    Executive VP & Chief Business Officer

    • Tenure: 12.6yrs
    • Compensation: US$1.11m
  • Chip Scarlett (68yo)

    CEO, President & Chairman of the Board

    • Tenure: 7.9yrs
    • Compensation: US$2.77m
  • Andrew Grethlein (55yo)

    Executive VP & COO

    • Tenure: 0.6yrs
    • Compensation: US$1.15m
  • Olivia Bloom (50yo)

    Executive VP of Finance

    • Tenure: 6.7yrs
    • Compensation: US$1.22m
  • Suzanne Messere

    Head of Investor Relations & Corporate Communications

    • Tenure: 0.0yrs
  • Aleksandra Rizo (44yo)

    Executive VP & Chief Medical Officer

    • Tenure: 0.6yrs
  • Shannon Odam

    Vice President of Human Resources

    • Tenure: 0.2yrs

Board Members

  • Karin Eastham (70yo)

    Lead Independent Director

    • Tenure: 0.7yrs
    • Compensation: US$239.40k
  • V. Lawlis (67yo)

    Independent Director

    • Tenure: 7.4yrs
    • Compensation: US$226.90k
  • Chip Scarlett (68yo)

    CEO, President & Chairman of the Board

    • Tenure: 7.9yrs
    • Compensation: US$2.77m
  • Bob Spiegel (70yo)

    Independent Director

    • Tenure: 9.3yrs
    • Compensation: US$221.90k
  • Susan Molineaux (65yo)

    Independent Director

    • Tenure: 6.9yrs
    • Compensation: US$216.90k
  • Dawn Bir (48yo)

    Independent Director

    • Tenure: 0.4yrs
  • Elizabeth O'Farrell (55yo)

    Independent Director

    • Tenure: 0.4yrs

Company Information

Geron Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Geron Corporation
  • Ticker: GERN
  • Exchange: NasdaqGS
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$271.329m
  • Shares outstanding: 188.42m
  • Website: https://www.geron.com

Number of Employees


Location

  • Geron Corporation
  • 149 Commonwealth Drive
  • Suite 2070
  • Menlo Park
  • California
  • 94025
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GERNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 1996
GONDB (Deutsche Boerse AG)YesCommon StockDEEURJul 1996
0IV3LSE (London Stock Exchange)YesCommon StockGBUSDJul 1996

Biography

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage devel ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 23:37
End of Day Share Price2019/08/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.